

Stock Sentiment Analysis Report

Revvity (RVTY)

Analysis Period: 2026-03-18 to 2026-04-17 (30 days)

Generated: 2026-04-17 09:58:07

Executive Summary


Sentiment analysis for Revvity (RVTY) from 2026-03-18 to 2026-04-17. Analyzed 78 items across FDA and news sources.

Sentiment Breakdown

Category	Count	Percentage
Positive	21	26.9%
Negative	20	25.6%
Neutral	37	47.4%
Total	78	100.0%

Overall Sentiment: NEUTRAL

Sentiment Trend Over Time



Key Findings

No key findings available.

Top Positive Events

Title	Source	Date	Score
Nephron Research gets more bullish on Revvity, upg...	news	2026-03-26	0.991
[Latest] Global Environmental Mass Spectrometry Ma...	news	2026-04-02	0.859
Catabolism of extracellular glutathione supplies c...	news	2026-03-18	0.856
Revvity Inc. stock outperforms competitors on stro...	alpha_vantage	2026-04-08	0.711
Revvity Gains on Diagnostics Strength, Faces China...	alpha_vantage	2026-04-06	0.681

Top Negative Events

Title	Source	Date	Score
Template-driven scaffolding of SCFFBXO42 regulates...	news	2026-04-15	-0.869
The E3 ubiquitin ligase mechanism specifying targe...	news	2026-03-18	-0.778
Ectopic NMDAR expression in cancer unmasks germlin...	news	2026-03-25	-0.660
Feasibility of deep learning-based cancer detectio...	pubmed	2026-04-17	-0.660
A μ -opioid receptor superagonist analgesic with mi...	news	2026-04-01	-0.612